JPMorgan raised the firm’s price target on Cellebrite (CLBT) to $24 from $22 and keeps an Overweight rating on the shares. The firm updating security software price targets for 2025 to reflect its view of current and anticipated market conditions.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.